Gene editing stocks remain a bet on scientific translation rather than near-term earnings. Investors are asking whether genome editing can progress from isolated proof-of-concept results into repeatable medicines that can be manufactured, reviewed by regulators and reimbursed at scale. That keeps the group volatile: clinical data, safety findings and regulatory signals can matter more than quarterly revenue, while negative earnings remain common across the field. The opportunity is substantial, but the timeline from promising edit to durable commercial product remains uncertain.
The structural case rests on better delivery, greater editing precision and a widening set of potential applications. Ex vivo CRISPR therapies are the most clinically mature sub-segment, while in vivo editing aims to deliver treatment directly to organs such as the liver. Base editing and prime editing add different approaches to specificity and DNA modification. The addressable market is also expanding beyond rare blood disorders toward cardiovascular, cardiometabolic, liver, autoimmune and oncology applications. The FDA’s June 2026 guidance on genome-editing gene therapy products, including its discussion of leveraging prior knowledge, adds definition to the regulatory pathway.
This countdown covers seven US-listed companies with direct exposure to those platforms and programs. The ordering runs from #7 to #1, combining thematic depth with business fundamentals such as revenue, losses, operating performance and the quality of recent earnings execution. Some names offer broad clinical portfolios, while others are more concentrated bets on a specific editing technology or disease area. The result is a spectrum of risk, from early-stage platform development to companies with more advanced therapeutic programs.
Methodology brief: We screened US-listed biotechnology companies with market capitalizations above $500 million and prioritized depth of exposure to gene editing, including platform ownership, clinical programs and breadth across ex vivo or in vivo applications. Business fundamentals then determined the ordering within the theme, with attention to revenue, growth, profitability, valuation data and earnings execution. The list is presented as a countdown from #7 to #1, with the best-ranked pick revealed at the end. Composite quality grades and analyst consensus are included as context rather than as standalone recommendations.
What they do. The company develops genetic medicines using Prime Editing, an approach that uses a programmable DNA-binding domain, a reverse-transcriptase domain and pegRNA to copy an edited sequence into a target genomic site without causing a double-stranded break. Its lead candidate is PM359 for chronic granulomatous disease in a Phase 1/2 trial, alongside preclinical PM577 for Wilson disease, PM647 for SERPINA1-related liver injury, liver programs and cystic fibrosis programs. Research and license arrangements with BMS, the Cystic Fibrosis Foundation, the Broad Institute and Beam broaden the platform’s external reach.
Why it fits. Prime Medicine is one of the clearest pure-play exposures to prime editing, a newer platform within the gene editing landscape. Its pipeline spans ex vivo and in vivo ambitions, with programs directed at blood, liver and cystic fibrosis applications. That breadth gives investors exposure to the technology’s potential beyond the more established CRISPR/Cas9 use cases, but much of the value still depends on clinical validation and development progress.
Numbers that matter. Revenue was $4.073 million, up 3.5% year over year, while EBITDA was negative $189.122 million. TTM EPS was negative $1.05, and the company had no trailing or forward P/E available. Profitability remains a major weakness: ROE was negative 3.7329%, ROA was negative 0.4652%, operating margin was negative 37.5087% and gross margin was negative 3489.5%. Those figures place Prime Medicine firmly in the platform-investment stage rather than the commercial earnings stage.
Recent momentum. The latest listed quarter, dated August 6, 2026, produced EPS of negative $0.24 versus an estimate of negative $0.24, a 0.0% surprise and no beat; the eight-quarter beat rate was 2/8. The consensus breakdown was two Buy ratings and four Holds, with an average target of $7.1136. That constructive target versus the company’s D+ composite grade highlights the gap between long-term platform expectations and current financial execution.
What they do. The company develops in vivo gene editing therapies through its ARCUS platform, which is designed for DNA insertion, removal and repair. Its programs include PBGENE-HBV for chronic hepatitis B, PBGENE-DMD for Duchenne muscular dystrophy, PBGENE-3243 for mitochondrial disease and iECURE-OTC for ornithine transcarbamylase deficiency. Collaboration agreements with TG Cell Therapy and iECURE extend the potential development and commercialization reach of the platform beyond the company’s own pipeline.
Why it fits. Precision BioSciences offers unusually direct exposure to in vivo editing, with an editing system aimed at more than one type of genetic intervention. The HBV program seeks to eliminate covalently closed circular DNA and inactivate integrated HBV DNA, while the broader pipeline covers excision, insertion and mitochondrial applications. That makes ARCUS a differentiated thematic vehicle, although the company remains dependent on clinical and partnership milestones.
Numbers that matter. Revenue was $45.055 million and increased 372.724% year over year, but EBITDA remained negative $35.148 million. TTM EPS was negative $1.32, with a listed forward P/E of 11.7786 and no trailing P/E. The company reported a 100.0% gross margin, but operating margin was negative 80.78% and net margin was negative 117.04%, showing that revenue growth has not yet translated into operating profitability.
Recent momentum. Precision BioSciences reported August 6, 2026 EPS of negative $0.71 against an estimate of negative $0.74, a 4.1% beat; its listed beat rate was 5/7. The March 2026 quarter was especially volatile, with EPS of $1.0059 against an estimate of negative $0.6433, a 256.4% surprise. Analysts had two Buy ratings, no listed Holds or Sells and an average target of $29.4, while the composite grade remained C-.
What they do. The company develops genomic medicines using a proprietary CRISPR-based gene editing platform. Its lead program, EDIT-401, is a one-time therapy designed to reduce LDL cholesterol by upregulating the LDL receptor, while the pipeline also includes programs for sickle cell disease, transfusion-dependent beta thalassemia and in vivo editing in other cells and tissues. A research collaboration with Juno Therapeutics adds experimental alpha-beta T-cell programs for solid and liquid tumors and autoimmune disease.
Why it fits. Editas combines the established ex vivo blood-disease application of CRISPR with a potentially broader in vivo focus through EDIT-401. The LDL-cholesterol program also connects gene editing to a large cardiometabolic opportunity rather than limiting the company to rare inherited disorders. Its oncology and autoimmune collaboration gives the platform additional thematic breadth, though the company still lacks commercial profitability.
Numbers that matter. Revenue was $47.005 million, up 2.323% year over year, while EBITDA was negative $81.035 million. TTM EPS was negative $0.66, and neither trailing nor forward P/E was available. Operating margin was negative 167.31%, net margin was negative 157.32% and gross margin was negative 80.7%, so the financial case remains tied to future clinical and partnership value rather than present earnings.
Recent momentum. In the August 5, 2026 quarter, Editas reported EPS of negative $0.15 versus an estimate of negative $0.30, a 50.0% beat; the eight-quarter beat rate was 5/8. The analyst mix was more cautious than the higher-ranked names, with one Buy, eight Holds and two Sells, producing a 3.4667 consensus score. The average target was $6, while the composite quality grade was C+.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
What they do. The company is a clinical-stage genome editing developer built around CRISPR/Cas9, with a modular platform supporting both in vivo and ex vivo therapies. Its key in vivo candidates include nexiguran ziclumeran, or NTLA-2001, for transthyretin amyloidosis and NTLA-2002 for hereditary angioedema. Additional collaborations cover allogeneic CAR-T, engineered NK-cell therapies, cystic fibrosis and other genomic medicines, giving Intellia a broad partnership and pipeline footprint.
Why it fits. Intellia is a substantial pure-play exposure to the in vivo CRISPR segment, particularly where liver-directed delivery could enable systemic treatment. Its two named lead programs target different diseases, while the wider portfolio reaches oncology, autoimmune disease and organs outside the liver. That breadth gives the company more shots at clinical validation, but it also leaves investors exposed to the safety, delivery and durability questions that define in vivo editing.
Numbers that matter. Revenue was $59.506 million, down 46.2% year over year, and EBITDA was negative $414.4 million. TTM EPS was negative $3.34, with no trailing or forward P/E available. Operating margin was negative 1472.26%, gross margin was negative 374.4% and ROE was negative 0.5544%; those results reflect a company investing heavily ahead of potential product commercialization rather than producing current operating leverage.
Recent momentum. Intellia’s August 6, 2026 EPS of negative $0.80 matched the estimate, producing a 0.0% surprise and no beat, although the listed beat rate was 6/7. The prior three reported quarters each exceeded estimates, including a 10.0% beat in May 2026. Analysts showed four Buys, six Holds and one Sell, with a 4.3448 consensus score and an average target of $24.
What they do. The company develops gene editing medicines for cardiovascular disease, using in vivo approaches intended to permanently alter liver targets. VERVE-101 and VERVE-102 are being evaluated in Phase 1b Heart trials for patients with heterozygous familial hypercholesterolemia or premature coronary artery disease, while VERVE-201 targets ANGPTL3 and VERVE-301 targets LPA. Partnerships and licenses with Beam, Acuitas, Novartis, Eli Lilly and the Broad Institute support the company’s delivery and editing strategy.
Why it fits. Verve is one of the most focused bets on expanding gene editing into cardiovascular and cardiometabolic disease. Its programs aim to turn off genes such as PCSK9, ANGPTL3 and LPA in the liver, potentially applying a one-time editing concept to targets commonly addressed with chronic medicines. That focus gives the company strong thematic purity, while the Phase 1b programs provide an identifiable clinical path for testing the approach.
Numbers that matter. Revenue was $59.613 million, up 4.79% year over year, while EBITDA was negative $201.615008 million. TTM EPS was negative $2.11, and no trailing or forward P/E was available. Gross margin was negative 253.0%, operating margin was negative 111.1% and ROE was negative 0.3426%, underscoring how far the company remains from earnings-based valuation.
Recent momentum. The latest listed earnings history records EPS of $0 in the November 11, 2025 quarter versus an estimate of negative $0.6995, a 100.0% surprise; the listed beat rate was 8/8. The analyst breakdown was three Buys and one Hold, resulting in a 4.5 consensus score and an average target of $13.125. Because the available earnings record is older than the other companies in this list, investors should distinguish that strong historical beat record from current clinical execution.
Pick #2Premium members only
Premium members see this pick's full breakdown — investment thesis, key financial metrics, recent earnings execution, and analyst consensus.
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
This monthly screen focuses on US-listed biotechnology companies with market capitalizations above $500 million and meaningful exposure to gene editing. We ranked the candidates first by depth of thematic exposure: ownership of an editing platform, number and stage of relevant programs, breadth across ex vivo and in vivo applications, and involvement in newer approaches such as base or prime editing. Business fundamentals then served as the tie-breaker, including revenue growth, EBITDA, margins, EPS, valuation data, earnings surprises and analyst consensus. The rankings are refreshed monthly because clinical results, regulatory developments and financial snapshots can materially change the risk profile of development-stage biotechnology companies.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
